Journal
JOURNAL OF LEUKOCYTE BIOLOGY
Volume 110, Issue 5, Pages 951-963Publisher
WILEY
DOI: 10.1002/JLB.4MA0920-627R
Keywords
adenovirus; antimicrobial peptides; immunopathology; immunotherapy; tuberculosis
Categories
Funding
- Consejo Nacional de Ciencia y Tecnologia (CONACyT) [367689]
Ask authors/readers for more resources
This study suggests that adenovirus-delivered antimicrobial peptides can serve as a promising adjuvant therapy for pulmonary tuberculosis by enhancing protective immune response, reducing bacterial load and inflammation, and potentially shortening the duration of antibiotic treatment.
As components of the innate immune response, antimicrobial peptides (AMPs) efficiently contribute to infection control and maintenance of a latent state in pulmonary tuberculosis (TB). As a therapeutic strategy, the administration of recombinant AMPs could be limited by enzymatic degradation and high production costs. Likewise, strategies based on the induction of AMPs have generated controversial results. In this study, 2 recombinant type-5 adenoviruses (Ad) expressing the human beta-defensin 3 (H beta D3) or cathelicidin (LL37) were assessed in a murine pulmonary TB model. Mice infected with either a high dose of a drug-sensitive (H37Rv) or a multidrug-resistant (MDR) strain of Mycobacterium tuberculosis (Mtb) were treated with a single administration of AdH beta D3, AdLL37, AdGFP (control vector expressing a green fluorescent protein), or saline solution (SS). Lungs were obtained to determine the bacterial burden, histologic damage, and cytokine expression at different time points. Mice treated with AdH beta D3 or AdLL37 showed significantly lower bacterial load and pneumonia, and higher proinflammatory cytokine expression than the control groups AdGFP and SS. A synergistic therapeutic effect could be observed when first- or second-line antibiotics (ABs) were administered with adenoviral therapy in animals infected with H37Rv or MDR strains, respectively. Adenovirus-delivered AMP's administration constitutes a promising adjuvant therapy for current anti-TB drugs by enhancing a protective immune response and potentially reducing current AB regimes' duration.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available